Home › Research › Brain tissue and pathology
Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia
Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A et al.. Brain : a journal of neurology, 2015-06-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Progressive cognitive decline in combination with a cerebrospinal fluid biomarker pattern of low levels of amyloid-β1-42 and high levels of total tau and phosphorylated tau is typical of Alzheimer's disease. However, several neurodegenerative disorders may overlap with Alzheimer's disease both in regards to clinical symptoms and neuropathology. In a uniquely large cohort of dementia patients, we examined the associations of cerebrospinal fluid biomarkers for Alzheimer's disease molecular pathology with clinical dementia diagnoses and disease severity.
What this study adds
Evidence grade: Moderate
By linking the Swedish Dementia Registry with a hospital laboratory database, this study assembled 5,676 people with a clinical dementia diagnosis and a complete set of spinal-fluid measurements of amyloid-β1-42, total tau and phosphorylated tau. It asked how this panel, whose pattern of low amyloid-β1-42 and high tau is "typical of Alzheimer's disease," relates to different dementia diagnoses and to disease severity, because other neurodegenerative disorders "may overlap" with Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Skillbäck, T., Farahmand, B. Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., et al. (2015). Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain : a journal of neurology. https://doi.org/10.1093/brain/awv181
Vancouver
Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain : a journal of neurology. 2015. doi:10.1093/brain/awv181. PMID: 26133663.
BibTeX
@article{skillback2015-26133663,
author = {Skillbäck, T. and Farahmand, B. Y. and Rosén, C. and Mattsson, N. and Nägga, K. and Kilander, L. and Religa, D. and Wimo, A. and others},
title = {{Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia}},
journal = {Brain : a journal of neurology},
year = {2015},
doi = {10.1093/brain/awv181},
pmid = {26133663},
url = {https://doi.org/10.1093/brain/awv181}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, several neurodegenerative disorders may overlap with Alzheimer's disease both in regards to clinical symptoms and neuropathology.
- In a uniquely large cohort of dementia patients, we examined the associations of cerebrospinal fluid biomarkers for Alzheimer's disease molecular pathology with clinical dementia diagnoses and disease severity.
- We cross-referenced the Swedish Dementia Registry with the clinical laboratory database at the Sahlgrenska University Hospital.
- The final data set consisted of 5676 unique subjects with a clinical dementia diagnosis and a complete set of measurements for cerebrospinal fluid amyloid-β1-42, total tau and phosphorylated tau.
Why it matters
By linking the Swedish Dementia Registry with a hospital laboratory database, this study assembled 5,676 people with a clinical dementia diagnosis and a complete set of spinal-fluid measurements of amyloid-β1-42, total tau and phosphorylated tau. It asked how this panel, whose pattern of low amyloid-β1-42 and high tau is "typical of Alzheimer's disease," relates to different dementia diagnoses and to disease severity, because other neurodegenerative disorders "may overlap" with Alzheimer's. It is a diagnostic-biomarker study and does not test any treatment or prevention.
Study details
- Evidence strengthModerate
How this study scored 56/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 218 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.8 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 4 / 6 | Cited 10.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 24 other studies in this library |
| Still being cited | 3 / 4 | Cited 64 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Henrik Zetterberg: h-index 196 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26133663) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.
Later studies that cite this one
24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain tissue and pathology from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.